A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naive Prostate Cancer

Trial Profile

A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naive Prostate Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 31 Aug 2017 Results (data cut off April 16, 2015) of prespecified 3 year followup analysis published in the Journal of Urology
    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results of a pre-specified 3-year follow-up, presented at the 2017 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top